Exagen (NASDAQ:XGN) Announces Earnings Results, Beats Estimates By $0.02 EPS

Exagen (NASDAQ:XGN) issued its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The company had revenue of $12.51 million for the quarter, compared to the consensus estimate of $13.55 million. During the same quarter in the prior year, the business posted ($0.31) earnings per share. Exagen updated its FY 2024 guidance to EPS.

Exagen Stock Performance

XGN opened at $2.90 on Friday. Exagen has a twelve month low of $1.30 and a twelve month high of $3.71. The company has a 50-day moving average price of $2.83 and a 200 day moving average price of $2.37. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.32 and a current ratio of 4.05.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Exagen in a research report on Wednesday.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).